Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the U.S. and Europe are diagnosed. For many, the road ahead is grim. Despite ...

A key cancer-fighting gene in leukemia is switched off—not broken—and scientists from The Jackson Laboratory (JAX) have found ...

Blood cancer treatment is entering a new era, bringing powerful breakthroughs that offer renewed hope to people living with leukemia, lymphoma, myeloma, and other blood cancers. Cutting-edge targeted ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I think that the last year to two years ...

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...

The University of Colorado Anschutz Gates Institute has received Investigational New Drug clearance from the U.S. Food and Drug Administration, marking the first chimeric antigen receptor (CAR) T-cell ...

Omeros Corporation (NASDAQ:OMER) on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...

(RTTNews) - Ipsen (IPSEY, IPN.PA) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza ...

Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia ...

Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 ...